Pulse Biosciences, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PLSE research report →
Companywww.pulsebiosciences.com
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.
- CEO
- Paul Arthur LaViolette
- IPO
- 2016
- Employees
- 75
- HQ
- Miami, CA, US
Price Chart
Valuation
- Market Cap
- $1.81B
- P/E
- -23.72
- P/S
- 2404.37
- P/B
- 26.68
- EV/EBITDA
- -23.64
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -91.08%
- Op Margin
- -10392.14%
- Net Margin
- -9929.03%
- ROE
- -86.67%
- ROIC
- -106.25%
Growth & Income
- Revenue
- $350.00K · 0.00%
- Net Income
- $-72,781,000 · -35.82%
- EPS
- $-1.08 · -17.39%
- Op Income
- $-76,939,000
- FCF YoY
- -49.27%
Performance & Tape
- 52W High
- $27.98
- 52W Low
- $12.56
- 50D MA
- $21.61
- 200D MA
- $17.61
- Beta
- 1.63
- Avg Volume
- 310.01K
Get TickerSpark's AI analysis on PLSE
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 11, 26 | DUGGAN ROBERT W | buy | 660,233 |
| May 11, 26 | LAVIOLETTE PAUL A | buy | 15,000 |
| May 11, 26 | LAVIOLETTE PAUL A | buy | 15,000 |
| May 11, 26 | DUGGAN ROBERT W | buy | 660,233 |
| Mar 23, 26 | UECKER DARRIN | other | 100,000 |
| Feb 18, 26 | Danahy Kevin Patrick | other | 5,000 |
| Feb 18, 26 | Danahy Kevin Patrick | other | 5,000 |
| Feb 18, 26 | Danahy Kevin Patrick | sell | 5,000 |
| Feb 12, 26 | Danahy Kevin Patrick | other | 20,000 |
| Feb 13, 26 | Danahy Kevin Patrick | other | 20,000 |
Our PLSE Coverage
We haven't published any research on PLSE yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate PLSE Report →